Evidence map›Paper›PMID 32463967›Full record

ArticleEuropean journal of heart failure2020

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.

Alexander R Lyon, Susan Dent, Susannah Stanway, Helena Earl, Christine Brezden-Masley, Alain Cohen-Solal, Carlo G Tocchetti, Javid J Moslehi, John D Groarke, Jutta Bergler-Klein and 42 more

Registry-linked trialOpen access · bronzeAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05081115 (The International Stress Echo Study to to Define the Future of Imaging), which is not on this map. Cited by 438 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
438citing papers in PubMed, 6 pooled it
57.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05081115 recruitingnot on this mapstarted 2021, after this paper: background citation

The International Stress Echo Study to to Define the Future of Imaging

Typeobservational_patient_registrySponsorFatebenefratelli HospitalRan2021 to 2030Enrolled10,000ConditionsCoronary Artery Disease, Heart Failure, Hypertrophic Cardiomyopathy, Congenital Heart DiseaseArmsABCDE-Stress Echo, SE diastolic assessment, SE Right ventricular function assessment, SE in heart donors
3 · Its place in the literature

Who cites it

438 citing papers in PubMed, 6 syntheses or guidelines pooled it, 735 citations in OpenAlex.

  1. Structured exercise and cardiac outcomes during anthracycline or anti-HER2 therapy in breast cancer: systematic review and meta-analysis of randomized trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Risk-guided cardioprotection in cardio-oncology.Nature cardiovascular research · 2026
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

378 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

52 authors at 20 institutions in 24 countries.

Alexander R LyonCardio-Oncology Service, Royal Brompton Hospital and Imperial College, London, UK.
Susan DentDuke Cancer Institute, Duke University, Durham, NC, USA.
Susannah StanwayBreast Unit, Royal Marsden Hospital, Surrey, UK.
Helena EarlDepartment of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
Christine Brezden-MasleyDivision of Medical Oncology, Sinai Health System, Mount Sinai Hospital, Toronto, Canada.
Alain Cohen-SolalUMR-S 942, Paris University, Cardiology Department, Lariboisiere Hospital, AP-HP, Paris, France.
Carlo G TocchettiDepartment of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University, Naples, Italy.
Javid J MoslehiCardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
John D GroarkeCardio-Oncology Program, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jutta Bergler-KleinDepartment of Cardiology, Medical University of Vienna, Vienna, Austria.
Vincent KhooDepartment of Clinical Oncology, Royal Marsden Hospital and Institute of Cancer Research, London, UK.
Li Ling TanDepartment of Cardiology, National University Heart Centre, Singapore, National University Health System, Singapore, Singapore.
Markus S AnkerDivision of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology, Charité Campus Benjamin Franklin, Berlin, Germany.
Stephan von HaehlingDepartment of Cardiology and Pneumology, University of Goettingen Medical Center, Goettingen, Germany.
Christoph MaackComprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany.
Radek PudilFirst Department of Medicine - Cardioangiology, Charles University Prague, Medical Faculty and University Hospital Hradec Kralove, Prague, Czech Republic.
Ana BaracMedStar Heart and Vascular Institute, Georgetown University, Washington, DC, USA.
Paaladinesh ThavendiranathanTed Rogers Program in Cardiotoxicity Prevention and Joint Division of Medical Imaging, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.
Bonnie KyUniversity of Pennsylvania, Philadelphia, PA, USA.
Tomas G NeilanCardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Yury BelenkovSechenov Medical University, Moscow, Russia.
Stuart D RosenCardio-Oncology Service, Royal Brompton Hospital and Imperial College, London, UK.
Zaza IakobishviliDepartment of Community Cardiology, Tel Aviv Jaffa District, Clalit Health Fund and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Aaron L SverdlovSchool of Medicine and Public Health, University of Newcastle and "Cancer and the Heart" Program, Hunter New England LHD, Newcastle, Australia.
Ludhmila A HajjarCardio-Oncology, Department of Cardio-Pneumology, University of São Paulo, São Paulo, Brazil.
Ariane V S MacedoSanta Cardio-Oncology, Santa Casa de São Paulo and Rede Dor São Luiz, São Paulo, Brazil.
Charlotte ManistyBarts Heart Centre and University College London, London, UK.
Fortunato CiardielloDepartment of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy.
Dimitrios FarmakisUniversity of Cyprus Medical School, Nicosia, Cyprus.
Rudolf A de BoerDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Hadi SkouriCardiology Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon.
Thomas M SuterDepartment of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
Daniela CardinaleCardioncology Unit, European Institute of Oncology, IRCCS, Milan, Italy.
Ronald M WittelesStanford University School of Medicine, Stanford, CA, USA.
Michael G FradleyUniversity of Pennsylvania, Philadelphia, PA, USA.
Joerg HerrmannDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Robert F CornellVanderbilt University Medical Center, Nashville, TN, USA.
Ashutosh WechelakerNational Amyloidosis Centre, University College London, London, UK.
Michael J MauroMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Dragana MilojkovicDepartment of Haematology, Hammersmith Hospital, Imperial College, London, UK.
Hugues de LavalladeDepartment of Haematological Medicine, King's College Hospital, London, UK.
Frank RuschitzkaUniversity Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
Andrew J S CoatsUniversity of Warwick, Warwick, UK.
Petar M SeferovicFaculty of Medicine and Serbian Academy of Sciences and Arts, University of Belgrade, Belgrade, Serbia.
Ovidiu ChioncelEmergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania.
Thomas ThumInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.
Johann BauersachsDepartment of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
M Sol AndresCardio-Oncology Service, Royal Brompton Hospital and Imperial College, London, UK.
David J WrightLiverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Liverpool, UK.
Teresa López-FernándezCardiology Service, Cardio-Oncology Unit, La Paz University Hospital and IdiPAz Research Institute, Ciber CV, Madrid, Spain.
Chris PlummerDepartment of Cardiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, UK.
Daniel LenihanCardio-Oncology Center of Excellence, Washington University in St Louis, St Louis, MO, USA.
Imperial College London · GBHarvard University · USMedizinische Hochschule Hannover · DEUniversity College London · GBUniversity of Pennsylvania · USVanderbilt University Medical Center · USAmerican University of Beirut Medical Center · LBAssistance Publique – Hôpitaux de Paris · FRBerlin-Brandenburger Centrum für Regenerative Therapien · DECarol Davila University of Medicine and Pharmacy · ROCharles University · CZDuke University · USEuropean Institute of Oncology · ITFederico II University Hospital · ITGeorgetown University · USGerman Centre for Cardiovascular Research · DEHospital La Paz Institute for Health Research · ESIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleKing's College Hospital · GBMayo Clinic in Arizona · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) TrialR01CA233610 · NCI · MAYO CLINIC ROCHESTER · PI HERRMANN, JOERG, RUDDY, KATHRYN JEAN · 2019 to 2024
$4.3M
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertensionR01HL141466 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEHI, JAVID J · 2019 to 2023
$3.3M
Department of Health 06/303/98NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA233610NHLBI NIH HHS R01 HL141466
6 · The paper itself

Abstract

This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.

Indexed as

Antineoplastic AgentsCardiovascular DiseasesNeoplasmsAgedAndrogen AntagonistsFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedRisk AssessmentRisk FactorsAndrogen AntagonistsAntineoplastic AgentsCardio-oncologyCardiotoxicityHeart failureRisk factorsRisk prediction

Identifiers

PMID32463967
PMCPMC8019326
OpenAlexW3031292493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.